New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 23, 2021, Novartis announced the FDA approval of Cosentyx (secukinumab), for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
Download PDF
Return to publications
